What is Synthace?
Headquartered in London and Boston, Synthace is redefining the biological research landscape through its flagship cloud software platform, Antha. By enabling biologists to program lab automation without the requirement for complex coding, Synthace effectively bridges the gap between digital design and physical experimentation. The platform provides a graphical user interface that streamlines the entire experimental lifecycle, from initial planning and execution to data collection and comprehensive analysis. This innovation is critical for organizations seeking to accelerate biological discovery and optimize research throughput in an increasingly data-driven industry.
How much funding has Synthace raised?
Synthace has raised a total of $72.1M across 4 funding rounds:
Angel/Seed
$2.1M
Series A
$9.4M
Series B
$25.6M
Series C
$35M
Angel/Seed (2013): $2.1M with participation from Sofinnova Partners
Series A (2017): $9.4M led by White Cloud Capital, Bioeconomy Capital., Sofinnova Partners, SOSV, Amadeus Capital Partners, and 11.2 Capital
Series B (2018): $25.6M supported by Horizons Ventures
Series C (2021): $35M featuring Sofinnova Partners and Horizons Ventures
Key Investors in Synthace
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability, with a hands-on approach to building companies from seed to later-stage.
Horizons Ventures
A venture firm focused on deep science and technology investments aimed at advancing humanity and supporting transformative, high-impact projects.
Amadeus Capital Partners
A London-based global technology venture capital firm that invests in high-growth companies across sectors including digital health, deep tech, and enterprise software.
What's next for Synthace?
With the infusion of $35M, Synthace is well-positioned to accelerate its product roadmap and expand its market reach. The company is expected to focus on enhancing the capabilities of the Antha platform, potentially integrating more advanced machine learning features to further automate complex biological workflows. As the life sciences industry continues to shift toward high-throughput, reproducible research, Synthace's role as a foundational technology provider becomes increasingly vital. The strategic focus will likely remain on scaling enterprise adoption and fostering partnerships with global research institutions to maintain its competitive edge in the burgeoning field of digital biology.
See full Synthace company page
